AstraZeneca Partner of Choice Network

Partnership Overview
The AstraZeneca Partner of Choice (AZ PoC) network is comprised of nine international cancer centers that possess strong translational research capabilities that can be utilized in order to accelerate cancer cures. Network partners are:

- OHSU Knight Cancer Institute (US)
- Johns Hopkins University (US)
- Institute Gustave Roussy (France)
- Cambridge Cancer Centre (UK)
- Princess Margaret Cancer Centre (Canada)
- Memorial Sloan Kettering Cancer Center (US)
- Peter MacCallum Cancer Center (Australia)
- Vall D’Hebron Institute of Oncology (Spain)
- Universidad de Navarra (Spain)

The Knight joined the network in July 2020, and is one of three network institutions in the US. The Knight was selected for its expertise in precision oncology trial design, research in the immune microenvironment, strength in cancer early detection, West Coast presence, and ability to offer first-in-human clinical trials.

Partner of Choice Fundamentals

- **Project Opportunities for Knight Investigators**
  - Proposals that address strategic priorities announced by AZ leadership at network meetings
  - Investigator-Initiated Trials (IITs) that may enhance AZ’s knowledge of its portfolio and/or new combinations
  - Collaborative research projects with AZ and other institutions in PoC Network

- **Connectivity**
  - Site participation in bi-annual PoC Network meetings (October and April) for broad information sharing
  - Annual site visit by AZ to each partner for site-specific highlights and brainstorming
  - Bi-weekly meetings between Knight & AZ alliance leads for project detail and tracking

- **Contractual obligations**
  - OHSU and all network partners have signed a Master Agreement which frames how partners work together, and outlines terms generally expected in project agreements. The Master Agreement allows open conversations and information sharing.
  - Each specific project will have its own contract and terms (including scope of work, budget, etc.). Project-specific contracts will always serve as prevailing legal agreements.
  - Broad CDA coverage allows the Knight and AZ to discuss project ideas and exchange confidential data. Confidentiality provisions extend to other Network partners if the content being discussed is PoC-related.

- **Partner of Choice Leadership**
  - Four designated site leads represent the Knight: Brian Druker, Lisa Coussens, Shivaani Kummar & Gordon Mills
  - The Knight’s has an on-site dedicated AZ PoC Team that facilitates project introduction, initiation and tracking:
    - Scientific liaisons: Liz Sturgill (solid tumor lead) & Cristina Tognon (heme malignancies lead)
    - Alliance manager: Dan Coleman (relationship and early detection lead)
  - Designated AstraZeneca liaison for project vetting, tracking & management: Rob Godin

How do I pitch a project?

- Collaborative projects – Contact Knight scientific liaisons and alliance manager
- IITs – Contact Knight scientific liaisons and alliance manager; ensure disease lead and Shivaani Kummar are informed
- Responding to AZ Requests for Proposals (RFPs) – Contact Knight scientific liaisons and alliance manager; team will coordinate with Rob Godin and relay proposals to AZ